Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function

scientific article published on 01 January 1988

Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1022283631
P356DOI10.1007/BF01061419
P698PubMed publication ID2834209

P2093author name stringG G Geyskes
B A van Schaik
H H van Rooij
A J Porsius
P A van der Wouw
P2860cites workPharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521Q41875348
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjectsQ42098372
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin systemQ42117586
Enalapril maleate and a lysine analogue (MK-521): disposition in manQ42264743
Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.Q42532122
Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.Q51634342
Lisinopril in hypertensive patients with and without renal failure.Q54141536
Drug dosage in patients with renal disease.Q54235166
Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitorQ70182769
P433issue1
P921main subjectpharmacokineticsQ323936
P304page(s)61-65
P577publication date1988-01-01
P1433published inEuropean Journal of Clinical PharmacologyQ1376707
P1476titlePharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function
P478volume34

Reverse relations

cites work (P2860)
Q40891443Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure
Q37950596Clinical pharmacokinetics of the newer ACE inhibitors. A review
Q47913024Clinical pharmacokinetics of vasodilators. Part I.
Q44917912Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency
Q36055004Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency
Q38378935Effects of cardiovascular disease on pharmacokinetics
Q72894682Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment
Q37268536Pharmacokinetics of newer drugs in patients with renal impairment (Part II).
Q35952552Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection
Q98163692Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model
Q90774040Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration
Q28333134The pharmacokinetics of benazepril relative to other ACE inhibitors

Search more.